[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344471-105":59,"doc-detail-344471-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-tri-component-organoid-model-reveals-field-cancerized-fibroblasts-as-key-drivers-of-luad-recurrence-and-drug-resistance","A tri-component organoid model reveals field-cancerized fibroblasts as key drivers of LUAD recurrence and drug resistance","","A tri-component organoid platform is developed to model lung adenocarcinoma (LUAD) beyond conventional systems by integrating patient-derived lung cancer tumoroids (LCTs), normal lung organoids (LOs), and field-cancerized fibroblasts. Spatial and bulk transcriptomic analyses identify LUAD-specific signatures and position cancer-associated fibroblasts (CAFs) as key drivers of a pro-tumorigenic tumor microenvironment that sustains survival and recurrence. Functional drug screening shows LCT selective sensitivity to pemetrexed while fibroblasts remain broadly resistant, and LO co-culture enables assessment of normal-tissue drug toxicity for more precise preclinical modeling.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-tri-component-organoid-model-reveals-field-cancerized-fibroblasts-as-key-drivers-of-luad-recurrence-and-drug-resistance/344471/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-tri-component-organoid-model-reveals-field-cancerized-fibroblasts-as-key-drivers-of-luad-recurrence-and-drug-resistance/344471.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What limitation do conventional LUAD models have, according to the document?","Question",{"text":112,"@type":113},"Conventional models fail to capture the dynamic interactions between cancer cells and the tumor microenvironment, limiting therapeutic advances.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does the tri-component organoid platform combine?",{"text":117,"@type":113},"It integrates patient-derived lung cancer tumoroids (LCTs), normal lung organoids (LOs), and field-cancerized fibroblasts to dissect heterogeneity and treatment resistance mechanisms.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the platform evaluate drug response and toxicity?",{"text":121,"@type":113},"Functional drug screening assesses drug sensitivity of LCTs versus the resistance of fibroblasts, while inclusion of LOs enables direct evaluation of drug toxicity on healthy lung tissue.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344471,1790169631,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Original Article  \nA tri-component organoid model reveals field-cancerized fibroblasts as key drivers of LUAD recurrence and drug resistance  \nKun Qiao,1,7 Yanhong Huang,2,7 Damien Chua,3,7 Jing Qu,4,7 Qibin Liao,5 Guoze Wang,2 Nguan Soon Tan,3,6 Shumin Liao,2 Liang Li,2 and Guangjian Zhang1  \n1Department of Thoracic Surgery, the First Affiliated Hospital, Xi’an Jiaotong University, Yan Ta West Road No.277, Xi’an, Shaanxi Province 710061, China; 2Department of Pharmacology, Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China; 3Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, 11 Mandalay Road, Singapore 308232, Singapore; 4Department of Pathogen Biology, Shenzhen Center for Disease Control and Prevention, Shenzhen 518073, China; 5Department of Thoracic Surgery, Shenzhen Third People’s Hospital, Shenzhen 518110, China; 6School of Biological Sciences, Nanyang Technological University Singapore, 60 Nanyang Drive, Singapore 637551, Singapore  \nLung adenocarcinoma (LUAD) is a leading cause of cancerrelated mortality, driven by extensive tumor heterogeneity and therapy resistance. Conventional models fail to capture the dynamic interactions between cancer cells and the tumor microenvironment (TME), limiting therapeutic advancements. Here, we present a tricomponent organoid platform integrating patient-derived lung cancer tumoroids (LCTs), normal lung organoids (LOs), and field-cancerized fibroblasts to dissect LUAD heterogeneity and treatment resistance mechanisms. This platform uniquely enables the simultaneous investigation of tumor-specific vulnerabilities, stromal contributions to drug resistance, and normal tissue toxicity. Spatial and bulk transcriptomic analyses reveal LUAD-specific gene signatures and highlight cancer-associated fibroblasts (CAFs) as key drivers of a pro-tumorigenic TME, reinforcing tumor survival and recurrence. Functional drug screening demonstrates that LCTs exhibit selective sensitivity to pemetrexed while fibroblasts remain universally resistant, underscoring stromal barriers to therapy. The inclusion of LOs allows direct assessment ofdrug toxicity on healthy lung tissue, bridging a critical gap in preclinical modeling. By capturing the tumor-stroma interplay with patient specificity, this organoid platform advances precision oncology, paving the way for more effective therapeutic strategies targeting both LUAD cells and the supportive microenvironment.  \nINTRODUCTION  \nLung cancer remains the most frequently diagnosed malignancy worldwide, accounting for approximately 12.4% of all newly diagnosed cancers and projected to reach 3.8 million new cases annually by 2070.1–3 Despite substantial advances in clinical research and therapeutic development, lung cancer continues to be the leading cause of cancer-related mortality, with an estimated 2 million deaths  \nreported in 2022 alone. 1,2,4 This burden is driven predominantly by non-small cell lung cancer (NSCLC), which comprises >80% of all lung cancer diagnoses and is associated with a 5-year overall survival rate of \u003C15% .  \nNSCLC encompasses two major histological subtypes: lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) . LUAD is distinguished by pronounced phenotypic and genomic heterogeneity, resulting in extensive inter-and intratumoral variability.5 Such heterogeneity complicates therapeutic decisionmaking, as tumor cells within and across patients can differ markedly in growth kinetics, invasion behavior, and molecular drivers. Clinically, this diversity translates into high relapse rates, up to 30%–50% of patients with early-stage LUAD develop metastatic recurrence following surgery resection, and nearly half ultimately relapse.5,6  \nReceived 24 April 2025; accepted 26 May 2026;  \n[https://doi.org/10.1016/j.omton.2026.201251](https://doi.org/10.1016/j.omton.2026.201251) .","cbCaiePxxQ1sW54N","https://ap.wps.com/l/cbCaiePxxQ1sW54N","pdf",7658502,12,"English","# Introduction\n## Lung adenocarcinoma heterogeneity and therapy resistance\n## Field cancerization and the role of cancer-associated fibroblasts","[{\"question\":\"What limitation do conventional LUAD models have, according to the document?\",\"answer\":\"Conventional models fail to capture the dynamic interactions between cancer cells and the tumor microenvironment, limiting therapeutic advances.\"},{\"question\":\"What does the tri-component organoid platform combine?\",\"answer\":\"It integrates patient-derived lung cancer tumoroids (LCTs), normal lung organoids (LOs), and field-cancerized fibroblasts to dissect heterogeneity and treatment resistance mechanisms.\"},{\"question\":\"How does the platform evaluate drug response and toxicity?\",\"answer\":\"Functional drug screening assesses drug sensitivity of LCTs versus the resistance of fibroblasts, while inclusion of LOs enables direct evaluation of drug toxicity on healthy lung tissue.\"}]","A tri-component organoid model reveals field-cancerized fibroblasts as key drivers of LUAD recurrence and drug resistance | PDF",1790053969,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8491bb33a8ce5d83c18f3e587fa92d4c.webp",983,1276,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36faa1bfc90a9a6aaad136578c2fbb56.webp",982,1275,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/faab717d2e0dc025e8084cfb35baaaec.webp",981,1273,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08c057a23467cbbca7a886eecdfe0303.webp",980,1272]